Table 1.
Pretreatment and treatment characteristics.
| Frequencies1 (%) | Definitive RT (n = 71) | Prostatectomy (n = 50) | p value |
|---|---|---|---|
| Biopsy Gleason score | |||
| ≤7 | 0 | 18 (37%) | <0.001 |
| ≥8 | 71 (100%) | 31 (63%) | |
| Clinical T stage | |||
| ≤T2 | 63 (88.7%) | 47 (96%) | 0.162 |
| T3 | 8† (11.3%) | 2†† (4%) | |
| Clinical N stage | |||
| NX/N0 | 67 (94.4%) | 49 (98%) | 0.323 |
| N1 | 4 (5.6%) | 1 (2%) | |
| Neoadjuvant and/or adjuvant ADT | |||
| Yes | 68 (95.8%) | 18 (36%) | <0.001 |
| No | 3 (4.2%) | 32 (64%) | |
| Preexisting diabetes | |||
| Yes | 9 (12.7%) | 10 (20%) | 0.276 |
| No | 62 (87.3%) | 40 (80%) | |
| Preexisting coronary artery disease | |||
| Yes | 15 (21.1%) | 7 (14%) | 0.317 |
| No | 56 (78.9%) | 43 (86%) | |
|
| |||
| Means2 (range) | |||
|
| |||
| Initial PSA: | 9.58 (1.1–19.0) | 11.52 (2.9–50.0) | 0.350 |
| Risk of LN involvement‡ | 13.02% (0–36.0%) | 8.91% (0–36.0%) | 0.006 |
| Age at initial treatment | 69.63 (50.44–83.61) | 60.91 (42.43–75.34) | <0.001 |
| Months of biochemical follow-up | 73.74 (12.37–172.0) | 60.03 (12.47–166.87) | 0.045 |
1Pearson χ 2 test. 2Independent samples Mann-Whitney U test. p value < 0.05 is considered statistically significant.
†3 patients clinically classified as T3 via MRI; 4 via DRE; and 1 via CT.
††2 patients clinically classified as T3 via MRI.
‡Based on updated Partin tables nomogram [6].
NX: lymph nodes not sampled; N0: lymph nodes negative for disease; N1: lymph nodes positive for disease; RT: radiotherapy; PSA: prostate specific antigen.